Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan
Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8438-8451
DOI: 10.1111/dom.71043 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.06.2026. Verfasst von Arshad Hussain und 9 weiteren Autor:innen. Beteiligte Einrichtung: North-West General Hospital, Peshawar, Pakistan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BF Bioscience Pvt. Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To evaluate the real‐world effectiveness, safety and patient‐reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost‐constrained setting.
Methods
This 30‐week, prospective, multicentre, non‐interventional study enrolled adults with T2DM initiating biosynthetic semaglutide. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to end of study (EOS). Secondary endpoints included changes in body weight, waist circumference, patient‐reported outcomes (DTSQs and SF‐36v2) and safety.
Results
Among 217 patients, mean HbA1c decreased from 9.27% to 7.41% at EOS (−1.86%; p < 0.001). At EOS, 76.6% achieved HbA1c < 8.0% and 38.7% achieved < 7.0%. Mean body weight decreased by −7.84 kg ( p < 0.001), with 76.5% achieving ≥ 5% weight loss. Significant reductions were also observed in body mass index and waist circumference. Treatment satisfaction and physical quality of life improved significantly. Adverse events were predominantly non‐serious and gastrointestinal. No severe hypoglycaemic episodes occurred.
Conclusions
In routine clinical practice, biosynthetic semaglutide was associated with clinically meaningful improvements in glycaemic control, body weight and physical quality of life. The safety profile remained consistent with established semaglutide therapy. Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12625000610437
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- North-West General Hospital, Peshawar, Pakistan.
- Umar Diabetes and Foot Care Centre and Umar Diabetes Foundation, Islamabad, Pakistan.
- Department of Medicine, Center for Diabetes and Liver Disease, Islamabad, Pakistan.
- Shifa International Hospitals Ltd., Islamabad, Pakistan.
- Omer Hospital, Lahore, Pakistan.
- City Hospital, Multan, Pakistan.
ORCID-Profile: Siew Chin Ong
Förderung
- BF Bioscience Pvt. Ltd.
Zitieren
APA
Hussain, A., Wahab, M. U., Qureshi, S., Raja, U. Y., Munir, A., Gardezi, S., Iqbal, M., Afzal, B., Butt, M. D., & Ong, S. C. (2026). Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Diabetes, Obesity and Metabolism, 28(9), 8438-8451. https://doi.org/10.1111/dom.71043
Vancouver
Hussain A, Wahab MU, Qureshi S, Raja UY, Munir A, Gardezi S, et al. Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Diabetes, Obesity and Metabolism. 2026;28(9):8438-8451. doi:10.1111/dom.71043
BibTeX
@article{Hussain2026,
author = {Hussain, Arshad and Wahab, Muhammad Umar and Qureshi, Saleem and Raja, Umar Yousaf and Munir, Atif and Gardezi, Shahnawaz and Iqbal, Musarrat and Afzal, Bilal and Butt, Muhammad Daoud and Ong, Siew Chin},
title = {Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {9},
pages = {8438--8451},
doi = {10.1111/dom.71043}
}
EUVIMED